BioCardia Inc
BCDA1.840USD
-0.290-13.62%
Market hours （ET）Quotes delayed by 15 min
8.61MMarket Cap
LossP/E TTM
More Details of BioCardia Inc Company
BioCardia, Inc. is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. It is advancing two cell therapy platforms derived from bone marrow such as CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being advanced as a cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS). Its autologous CardiAMP and allogeneic CardiALLO cell therapies intended for cardiac indications of HFrEF and CMI are enabled by its Helix minimally invasive intramyocardial therapeutic delivery platform.
Company Info
Ticker SymbolBCDA
Company nameBioCardia Inc
IPO dateNov 13, 1996
CEODr. Peter Altman, Ph.D.
Number of employees17
Security typeOrdinary Share
Fiscal year-endNov 13
Address320 Soquel Way
CitySUNNYVALE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code94085
Phone16502260123
Websitehttps://www.biocardia.com/
Ticker SymbolBCDA
IPO dateNov 13, 1996
CEODr. Peter Altman, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
167.70K
+16.78%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
144.54K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
118.69K
+49.48%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
47.95K
+11.17%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
+417.27%
Mr. Bill Facteau
Mr. Bill Facteau
Independent Director
Independent Director
13.12K
--
Mr. Jay M. Moyes, CPA
Mr. Jay M. Moyes, CPA
Independent Director
Independent Director
3.62K
-0.06%
Mr. Edward Gillis
Mr. Edward Gillis
Senior Vice President - Devices
Senior Vice President - Devices
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Peter Altman, Ph.D.
Dr. Peter Altman, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
167.70K
+16.78%
Mr. Andrew Scott Blank
Mr. Andrew Scott Blank
Independent Chairman of the Board
Independent Chairman of the Board
144.54K
--
Dr. Simon H. Stertzer, M.D.
Dr. Simon H. Stertzer, M.D.
Independent Director
Independent Director
118.69K
+49.48%
Mr. Jim Allen
Mr. Jim Allen
Independent Director
Independent Director
109.66K
--
Mr. David Mcclung
Mr. David Mcclung
Chief Financial Officer
Chief Financial Officer
47.95K
+11.17%
Dr. Richard M. Krasno, Ph.D.
Dr. Richard M. Krasno, Ph.D.
Independent Director
Independent Director
16.27K
+417.27%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 10
Updated: Sat, May 10
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Satterfield (Thomas A Jr)
7.12%
Altman (Peter)
3.08%
Blank (Andrew Scott)
2.65%
Stertzer (Simon H)
2.18%
Allen (Jim L)
2.01%
Other
82.97%
Shareholders
Shareholders
Proportion
Satterfield (Thomas A Jr)
7.12%
Altman (Peter)
3.08%
Blank (Andrew Scott)
2.65%
Stertzer (Simon H)
2.18%
Allen (Jim L)
2.01%
Other
82.97%
Shareholder Types
Shareholders
Proportion
Individual Investor
18.68%
Investment Advisor
3.17%
Corporation
2.66%
Investment Advisor/Hedge Fund
1.34%
Other
74.16%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
50
1.41M
25.85%
+377.00K
2025Q1
56
1.40M
27.94%
+375.61K
2024Q4
58
1.08M
23.60%
+180.41K
2024Q3
57
740.61K
21.37%
-175.94K
2024Q2
60
625.47K
23.03%
-304.05K
2024Q1
60
735.85K
38.95%
-141.63K
2023Q4
61
789.41K
56.72%
+313.00
2023Q3
59
767.08K
57.64%
+35.10K
2023Q2
59
692.26K
54.51%
+36.66K
2023Q1
55
606.10K
49.67%
-69.96K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Satterfield (Thomas A Jr)
388.15K
7.12%
+286.78K
+282.91%
Dec 31, 2024
Altman (Peter)
167.70K
3.08%
+24.10K
+16.78%
Jun 30, 2025
Blank (Andrew Scott)
144.54K
2.65%
--
--
Apr 23, 2025
Stertzer (Simon H)
118.69K
2.18%
+39.29K
+49.48%
Mar 05, 2025
Allen (Jim L)
109.66K
2.01%
-1.00
-0.00%
Dec 31, 2024
Frost Gamma Investments Trust
85.76K
1.57%
-18.98K
-18.12%
Mar 26, 2024
CM Management, LLC
75.00K
1.38%
+50.00K
+200.00%
Mar 31, 2025
Susquehanna International Group, LLP
59.95K
1.1%
+16.11K
+36.74%
Mar 31, 2025
Stertzer Family Trust
59.20K
1.09%
-2.00
-0.00%
Dec 31, 2024
Mcclung (David)
47.95K
0.88%
+4.82K
+11.17%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
Date
Type
Ratio
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
May 21, 2024
Merger
15<1
